Furthermore, we [14] and others have now found that IRF8 can be expressed, but typically is epigenetically silenced in non-hematopoietic malignancies [15, 16] or repressed by immune-associated soluble factors during tumor-induced alterations in myelopoiesis [17]. This evidence concerns the gene IRF8 and neoplasm.